Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors

[Image: see text] Glycogen synthase kinase 3 (GSK3) remains a therapeutic target of interest for diverse clinical indications. However, one hurdle in the development of small molecule GSK3 inhibitors has been safety concerns related to pan-inhibition of both GSK3 paralogs, leading to activation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaral, Brenda, Capacci, Andrew, Anderson, Trip, Tezer, Ceren, Bajrami, Bekim, Lulla, Mukesh, Lucas, Brian, Chodaparambil, Jayanth V., Marcotte, Douglas, Kumar, P. Rajesh, Murugan, Paramasivam, Spilker, Kerri, Cullivan, Mike, Wang, Ti, Peterson, Anton C., Enyedy, Istvan, Ma, Bin, Chen, TeYu, Yousaf, Zain, Calhoun, Michael, Golonzhka, Olga, Dillon, Gregory M., Koirala, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020971/
https://www.ncbi.nlm.nih.gov/pubmed/36812145
http://dx.doi.org/10.1021/acschemneuro.2c00476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020971/
https://www.ncbi.nlm.nih.gov/pubmed/36812145
http://dx.doi.org/10.1021/acschemneuro.2c00476

Ejemplares similares